Indoco and Amneal have already begun to identify several more ophthalmic products to pursue as well as other therapeutic categories and dosage forms. The two companies fully expect this agreement to expand significantly in the near term and to last many years.
With balanced input from both Amneal and Indoco, funding for developing these products will be equally shared. Likewise, the financial benefit from the sale of these products will be shared for years.
INDOCO REMEDIES Limited, headquartered in India, is a fully integrated research based pharmaceutical company, producing a wide range of high quality, affordable generic medicines trusted across the Globe. Indoco enjoys a dominant position in the domestic Indian market and its products are distributed in over 30 countries, including USA, Germany, UK and Australia. The state-of-the-art R&D facilities cover 70,000 sq ft, employ 100 scientists and support a manufacturing plant with approvals from USFDA, UK-MHRA, German Regulatory Authorities and ANVISA Brazil, reflecting the Company's commitment to being a leader in the generic space worldwide.
AMNEAL PHARMACEUTICALS LLC, headquartered in Paterson, NJ, is a
USA-based firm that develops, manufacturers and distributes generic
pharmaceutical products regulated and approved by the US FDA. Positioned as
"Generic's New Generation," the company utilizes diverse R&D and
manufacturing expertise to conceive breakthrough developments with lasting
impact. Vigorous ANDA growth and broad product acquisitions are keys of
Amneal's strategic growth plan, as is the company's commitment to building
deep relationships with its customer b
|SOURCE Amneal Pharmaceuticals|
Copyright©2007 PR Newswire.
All rights reserved